Program
Stem Cell
Also written as “Stem cells”, “Single Dose MPCs Injection” and “Autologous Bone Marrow CD34+ Stem Cells”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Myocardial Infarction · Retinal Vein Occlusion · Coronary Artery Disease · Anemia, Sickle Cell, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Honya Medical | 21 open or running | phase 2since Aug 6, 2019 | Aug 6, 2019 | none ahead |
| Kang Stem Biotech | 20 open or running | phase 2since Nov 7, 2013 | Nov 7, 2013 | none ahead |
| SMSbiotech | 22 open or running | phase 2since Sep 22, 2026 | Mar 13, 2025 | Dec 2026phase 1 · NCT06986070 |
| AlloCure | 10 open or running | phase 2since May 17, 2012 | May 17, 2012 | none ahead |
| BRL Medicine | 11 open or running | no phasesince Feb 23, 2024 | Feb 23, 2024 | none ahead |
| Mesoblast | 10 open or running | phase 2since Feb 3, 2011 | Feb 3, 2011 | none ahead |
| StemCells | 10 open or running | phase 1since Nov 5, 2010 | Nov 5, 2010 | none ahead |
| Stemedica Cell Technologies | 10 open or running | phase 2since Jan 14, 2013 | Jan 14, 2013 | none ahead |
| Stempeutics Research Pvt | 10 open or running | phase 2since Apr 17, 2009 | Apr 17, 2009 | none ahead |
| The Emmes | 10 open or running | phase 2since Jun 6, 2019 | Jun 6, 2019 | none ahead |
Also a collaborator on its studies: cardiocell-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2009First study: phase 2 study in Myocardial InfarctionNew to Stempeutics Research PvtStempeutics Research Pvt · NCT00883727 · 20 enrolled · India
- Nov 5, 2010StemCells's first study: phase 1 study in Neuronal Ceroid-LipofuscinosesNew to StemCellsStemCells · NCT01238315 · United States
- Feb 3, 2011Mesoblast's first study: phase 2 study in Intervertebral Disc DegenerationNew to MesoblastMesoblast · NCT01290367 · 100 enrolled · United States, Australia
- May 17, 2012AlloCure's first study: phase 2 study in Acute Kidney InjuryNew to AlloCureAlloCure · NCT01602328 · 156 enrolled · United States, Canada
- Jan 14, 2013Stemedica Cell Technologies's first study: phase 2 study in ST Elevation Myocardial InfarctionNew to Stemedica Cell TechnologiesStemedica Cell Technologies · NCT01770613 · United States
- Nov 7, 2013Kang Stem Biotech's first study: phase 2 study in Crohn DiseaseNew to Kang Stem BiotechKang Stem Biotech · NCT02000362 · 24 enrolled · Korea, Republic of
- Sep 27, 2016Phase 1 study in PsoriasisKang Stem Biotech · NCT02918123 · 9 enrolled · Korea, Republic of
- Jun 6, 2019The Emmes's first study: phase 2 study in Retinal Vein OcclusionNew to The EmmesThe Emmes · NCT03981549 · 16 enrolled · United States
- Aug 6, 2019Honya Medical's first study: phase 1 study in Coronary Artery DiseaseNew to Honya MedicalHonya Medical · NCT04052191 · 40 planned · Taiwan
- Aug 6, 2019Phase 2 study in Myocardial InfarctionHonya Medical · NCT04050163 · 11 enrolled · Taiwan
- Feb 23, 2024BRL Medicine's first study: no phase study in Anemia, Sickle CellNew to BRL MedicineBRL Medicine · NCT06287086 · 1 planned
- Mar 13, 2025SMSbiotech's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to SMSbiotechSMSbiotech · NCT06986070 · 18 planned · Australia
- Sep 22, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedSMSbiotech · NCT07871890 · 125 planned · United States
Ahead
- Dec 2026Primary completion: phase 1 study in Pulmonary Disease, Chronic ObstructiveSMSbiotech · NCT06986070
- Oct 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveSMSbiotech · NCT07871890
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07871890Pulmonary Disease, Chronic Obstructive · United States | 2 | Not yet recruiting | SMSbiotech | Oct 2027 | 125 |
| NCT06986070Pulmonary Disease, Chronic Obstructive · Australia | 1 | Recruiting | SMSbiotech | Dec 2026 | 18 |
| NCT06287086Anemia, Sickle Cell | – | Not yet recruiting | BRL Medicine | Aug 20, 2025 | 1 |
| NCT04052191Coronary Artery Disease · Taiwan | 1 | Not yet recruiting | Honya Medical | Jan 1, 2026 | 40 |
| NCT04050163Myocardial Infarction · Taiwan | 2 | Completed | Honya Medical | May 4, 2023 | 11 |
| NCT03981549Retinal Vein Occlusion · United States | 2 | Completed | The Emmes | Nov 7, 2023 | 16 |
| NCT02918123Psoriasis · Korea, Republic of | 1 | UNKNOWN | Kang Stem Biotech | Dec 2021 | 9 |
| NCT02000362Crohn Disease · Korea, Republic of | 2 | UNKNOWN | Kang Stem Biotech | Sep 2018 | 24 |
| NCT01770613ST Elevation Myocardial Infarction · United States | 2 | Withdrawn | Stemedica Cell Technologies | May 2016 | 0 |
| NCT01602328Acute Kidney Injury · United States, Canada | 2 | Terminated | AlloCure | Jun 2014 | 156 |
| NCT01290367Intervertebral Disc Degeneration · United States, Australia | 2 | Completed | Mesoblast | Jul 2013 | 100 |
| NCT01238315Neuronal Ceroid-Lipofuscinoses · United States | 1 | Withdrawn | StemCells | Apr 2011 | 0 |
| NCT00883727Myocardial Infarction · India | 2 | Completed | Stempeutics Research Pvt | May 2010 | 20 |
How it is read
Names in the registry
- “Stem cells”, 4 entries
- “Single Dose MPCs Injection”, 2 entries
- “Autologous Bone Marrow CD34+ Stem Cells”, 1 entry
- “MCRcI® stem cells”, 1 entry
- “BRL-101 autologous hematopoietic stem and progenitor cells injection”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 2 studies
- Myocardial Infarction, 2 studies
- Retinal Vein Occlusion, 1 study
- Coronary Artery Disease, 1 study
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.